SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?
PRCT 30.93-3.1%Nov 10 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gerald Thomas who wrote (166)5/13/1997 8:33:00 AM
From: Douglas   of 455
 
Mr. Erck's letter to the shareholders shows us the direction that Procept is taking. I liked his comments that: "based on these studies we hope to initiate additional Phase I/II trials later this year", "as I write this letter, we are involved in several discussions with potential pharmaceutical partners who have recognized the scientific value of these new initiatives", "we are aware of the need to create value for our investors and are dedicated to achieving this goal", "these early stage programs (tuberculosis, autoimmune disorders) have moved quickly and we expect to create scientific and commercial value throughout this year."

The front and back pages of the folder holding the 10K also mentioned some other information. "Procept and VacTex have put in place a strong CD1 receptor/TB vaccine research program. Studies in an in vivo model of TB are underway." "In addition, the Company has recently established a collaboration with the NIH to develop novel treatments for TB."

I believe that the survival of this company now depends on the results of the Phase I trials. If women tolerate the gel with no problems, Procept should be able to obtain additional financing. I don't see many announcements till June 16 (Annual Meeting). Gerald, do you see a different schedule of events?

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext